LSN News › India

World · India Bureau

NPPA enforces compliance with revised cancer drug prices across India

India's pharmaceutical regulator has directed state drug controllers to monitor adherence to newly fixed prices for 137 anti-cancer medications. Non-compliance could trigger enforcement action, the National Pharmaceutical Pricing Authority has warned.

LSN India · 13 November 2026

NPPA enforces compliance with revised cancer drug prices across India

The National Pharmaceutical Pricing Authority (NPPA) has issued directives to state drug controllers nationwide to ensure strict compliance with recently revised ceiling prices for 137 anti-cancer drugs. The move aims to prevent overcharging and ensure affordable access to critical oncology medications across the country.

State authorities have been instructed to intensify monitoring at retail and wholesale levels to verify that pharmaceutical companies and distributors are adhering to the newly prescribed price bands. The regulator has cautioned that failure to comply with the revised pricing structure will invite regulatory action and penalties.

The NPPA's action comes as part of its broader mandate to regulate drug prices and protect consumers from excessive costs. The cancer drug price revision is expected to benefit patients requiring long-term treatment, reducing out-of-pocket expenses for oncology care.

State drug controllers have been asked to conduct regular inspections and file compliance reports with the NPPA. The regulator has also directed officials to address consumer complaints regarding price violations promptly and take corrective measures where necessary.